Hafiz Abdul-Aziz

Dr. Mohd Hafiz Abdul-Aziz is an Early Career Research Fellow and Clinical Research Pharmacist at the University of Queensland Centre for Clinical Research (UQCCR), Australia. He currently leads the Clinical Dosing Studies and Knowledge Translation Workstream within the Antimicrobial Optimisation Group and the Centre for Research Excellence for Personalising Antimicrobial Dosing to Reduce Resistance (CRE RESPOND) at UQCCR. Dr. Abdul-Aziz holds a Bachelor of Pharmacy (IIUM) and a Master of Clinical Pharmacy (UKM) from Malaysia and completed his PhD at the University of Queensland in 2016. His doctoral thesis focused on pharmacokinetic/pharmacodynamic-optimised beta-lactam dosing in critically ill patients.

As a clinical pharmacist with a strong interest in clinical research, Dr. Abdul-Aziz is particularly focused on multi-centre and multi-national collaborations. His current research program aims to develop innovative methods for optimising antimicrobial dosing and delivery to improve patient outcomes in the ICU. He has extensive experience in designing and conducting multi-national clinical pharmacokinetic studies in the ICU. Over the past five years, he has led or coordinated eight multi-national antimicrobial pharmacokinetic studies, including the ASAP ECMO, BLING 3, BLING 3 PK/PD, and PNEUDOS studies.

Dr. Abdul-Aziz is a Fellow of the International Society of Antimicrobial Chemotherapy (ISAC) and serves as the Chair of the Infections in the ICU and Sepsis Working Group of ISAC. He has maintained active collaborations with over 100 collaborators from 36 countries.